Toll Free (US/Canada): 1-888-778-7886
Estrogen Receptor-Positive (ER+) Breast Cancer Pipeline to Witness Huge R&D Investment in the Coming Years
According to a new research report “Estrogen Receptor-Positive (ER+) Breast Cancer Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Estrogen Receptor-Positive (ER+) breast cancer currently exhibits a pipeline with 46 active drug candidates.
ER+ breast cancer pipeline offers novel therapeutic targets for the treatment of breast cancer
The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates, of which nine products are in Phase III, 16 products in Phase II, 18 products in Phase I, and three products are in Pre-Clinical stage. The development of 14 ER+ breast cancer drug candidates was found to be inactive, and 14 products were discontinued. ER+ breast cancer is the most common type of breast cancer diagnosed and refers to the cancer cells that have receptors on their surface to bind with estrogen. Breast cancer is a syndrome that affects the breast tissues. In breast cancer, cells in the breast grow in an uncontrollable manner and form tumor, which can be felt as a lump or can be viewed under x-ray. Invasion of new therapeutic agents, such as gene therapy, cell therapy and monoclonal antibodies are expected to provide an effective and concrete treatment for the disease, more in the light of the new technologies available.
Insights on pipeline analysis
As per the findings of the research, a major share of ER+ breast cancer pipeline drug candidates are being developed to be administered by oral route and rest by intravenous route and subcutaneous route. Most of the therapeutic candidates are being developed to be administered by oral route due to high patient compliance.
ER+ BREAST CANCER PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)
Several companies are developing ER+ breast cancer drug candidates in different phases. Novartis AG, Syndax Pharmaceuticals, Tesaro, Inc. and others have their ER+ breast cancer drug candidates in Phase III stage of development. Novartis AG has three drug candidates in Phase III stage and two drug candidates in Phase I clinical stage.
Chemical Genomics-Based Discovery Platform for ER+ breast cancer drug development
Chipscreen Biosciences, Ltd. is using chemo genomics approach for the development of Chidamide for ER+ breast cancer. The approach connects small molecule structures to disease targets and therapeutic functions to accelerate the discovery process by effectively comparing the molecular profiles of successful drugs, failed drugs, and classical toxins. For the discovery of small molecules, the company is following a comprehensive systemic approach, integrated with in silico design, chemistries, high content screening, global gene expression profiling, and informatics in the early stage of discovery.
Phase III - Highest stage of development for ER+ breast cancer pipeline
There are nine ER+ breast cancer drug candidates in the Phase III stage of development. Buparlisib is a Phase III stage drug candidate introduced by Novartis Pharmaceuticals for the treatment of hormone receptor-positive (HR+) breast cancer. It is a small molecule that inhibits PI3K and is administered by oral route. The product is also in Phase II stage of development for the treatment of ER+ breast cancer.
Major companies collaborate for the development of ER+ breast cancer pipeline
The research finds that different companies have collaborated for the development of ER+ breast cancer. In May 2015, Tesaro, Inc entered in a collaboration with Merck & Co. to evaluate the combination of Tesaro’s Niraparib plus Merck’s anti-PD1 therapy, Keytruda (pembrolizumab), in a Phase 1/2 clinical trial. Also, in January 2016, Radius Health, Inc. entered in a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901 with LEE011 for advanced breast cancer.
Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., Novartis AG, Ipsen, Syndax Pharmaceuticals, Inc., Tesaro, Inc Astellas Pharma Inc., AstraZeneca plc, and Bayer AG.
ER+ Breast Cancer Pipeline Analysis
Note: In the pipeline analysis, inactive and discontinued products have been analyzed separately.